Persistent Depressive Disorder
A mild but long-term form of depression.
Dysthymia is defined as a low mood occurring for at least two years, along with at least two other symptoms of depression.
Examples of symptoms include lost interest in normal activities, hopelessness, low self-esteem, low appetite, low energy, sleep changes, and poor concentration.
Treatments include medications and talk therapy.
Cluster Number:
Wiki Number: PW161
Diagnosis: Persistent Depressive Disorder-Dysthymia
US Patients: 3-6% during lifetime
World Patients: 105 Mil per year (1.5% of the population)
Sex Ratio:
Age Onset: 21, before 21 called “early onset”
Brain Area: In women, the corpus callosum and frontal lobes differ from normal; the amygdala, insula (sadness) and cingulate gyrus(emotions)
Symptoms: 2-years for adults; 1-year for children, deep depression with longer-lasting insomnia or hypersomnia and low self-esteem
Progression: little enjoyment in anything, suicidal behaviors, other disorders or addictions; hopelessness about life
Causes: genetic for 50% of cases; 75% have other physical illnesses, disorders or addictions; 95% have episodes of major depression.
Medications: antidepressants, but 6-8 weeks before progress; SSRIs, lithium
Therapies: cognitive therapy, better sleep, exercise
Youtube Video:
Life with Persistent Depressive Disorder (also known as Dysthymia)
Amazon or Library Book: Persistent Depressive Disorders
Click the book to link or order from Amazon.
Support Group: feelingkindablue.org; 866-728-7983
(Provident Behavioral Health)
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.04
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Personality and neuropsychiatric symptoms in individuals diagnosed with long COVIDby Asia Avinir on December 20, 2024
CONCLUSION: The study underscores the significance of incorporating psychological interventions into treatment plans to alleviate distress symptoms associated with cognitive decline in conditions like Long COVID.
- A comparative study of depressive and anxiety symptoms, insomnia, and sleepiness in patients with obstructive sleep apnea, restless legs syndrome, or both (CO-ROSA): preliminary findings from a retrospective studyby Lourdes M DelRosso on December 20, 2024
Patients with obstructive sleep apnea (OSA), restless legs syndrome (RLS), or both may exhibit varied manifestations of depressive and anxiety symptomatology, reflecting the complex interplay between sleep disturbances, neurotransmitter imbalances, and psychosocial stressors in these often overlapping conditions. The aim of this study was to compare depressive and anxiety symptomatology, insomnia severity, and sleepiness in these conditions. Patients were enrolled and subdivided into those with...
- Effect of serum antioxidants on cognitive dysfunction in first-episode and drug-naive patients with major depressive disorderby Ziyun Zhang on December 18, 2024
CONCLUSIONS: As serum antioxidants, ALB and UA may serve as biomarkers of cognitive function in patients with MDD. Our findings contribute to the understanding of the potential ability of serum antioxidants to predict cognitive decline in patients with MDD.
- Single-Case Study of the Feasibility of Parent Training and Change in Parenting in Comparison to Baseline, in Adolescents With a Major Depressive Disorderby Christiaan van den Brink on December 11, 2024
Existing research has shown that parental behavior can influence the onset and persistence of adolescent depression; however, the initial treatment guidelines do not include parental involvement, and there is no established protocol for engaging parents. For this study, the Doepressie parent training protocol was designed to teach parents ways to help their child cope with depression, and this study sought to evaluate the feasibility and changes in parenting of combining individual cognitive...